"Prednisone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
| Descriptor ID |
D011241
|
| MeSH Number(s) |
D04.210.500.745.432.719.702
|
| Concept/Terms |
Prednisone- Prednisone
- Dehydrocortisone
- delta-Cortisone
|
Below are MeSH descriptors whose meaning is more general than "Prednisone".
Below are MeSH descriptors whose meaning is more specific than "Prednisone".
This graph shows the total number of publications written about "Prednisone" by people in this website by year, and whether "Prednisone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 4 | 5 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 5 | 6 |
| 1999 | 2 | 1 | 3 |
| 2000 | 1 | 3 | 4 |
| 2002 | 1 | 5 | 6 |
| 2003 | 1 | 6 | 7 |
| 2004 | 1 | 2 | 3 |
| 2005 | 0 | 4 | 4 |
| 2006 | 1 | 5 | 6 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 8 | 8 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 6 | 7 |
| 2012 | 0 | 4 | 4 |
| 2013 | 1 | 5 | 6 |
| 2014 | 0 | 8 | 8 |
| 2015 | 2 | 7 | 9 |
| 2016 | 1 | 5 | 6 |
| 2017 | 0 | 4 | 4 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 3 | 3 |
| 2020 | 0 | 6 | 6 |
| 2021 | 2 | 6 | 8 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
| 2025 | 1 | 3 | 4 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prednisone" by people in Profiles.
-
Multibacillary leprosy relapse presenting as hypopigmented patches and concurrent erythema nodosum leprosum after initial multidrug therapy. Dermatol Online J. 2026 Jan 05; 31(6).
-
Successful Treatment of Double-Positive Rapidly Progressive Glomerulonephritis: A Case Report. J Investig Med High Impact Case Rep. 2025 Jan-Dec; 13:23247096251365418.
-
Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy. Transplant Cell Ther. 2025 Oct; 31(10):826.e1-826.e10.
-
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv. 2025 May 27; 9(10):2461-2472.
-
Impact of hydrocortisone vs prednisone therapy on postsurgical recovery in patients with endogenous hypercortisolism: a prospective cohort study. Eur J Endocrinol. 2025 Apr 30; 192(5):621-630.
-
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure. Leuk Lymphoma. 2025 Aug; 66(8):1437-1446.
-
Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
-
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood Adv. 2024 04 09; 8(7):1612-1620.
-
Impact of follow-up adherence on disease activity in childhood-onset systemic lupus erythematosus (cSLE). Lupus. 2023 May; 32(6):799-803.
-
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 11 03; 387(18):1649-1660.